{"id":"https://openalex.org/W2139083181","doi":"https://doi.org/10.1345/aph.1l570","title":"Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia","display_name":"Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia","publication_year":2009,"publication_date":"2009-03-31","ids":{"openalex":"https://openalex.org/W2139083181","doi":"https://doi.org/10.1345/aph.1l570","mag":"2139083181","pmid":"https://pubmed.ncbi.nlm.nih.gov/19336654"},"language":"en","primary_location":{"id":"doi:10.1345/aph.1l570","doi":"https://doi.org/10.1345/aph.1l570","is_oa":false,"landing_page_url":"https://doi.org/10.1345/aph.1l570","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113785207","display_name":"Timothy G Tyler","orcid":"https://orcid.org/0009-0003-6208-4502","observed_orcids":["https://orcid.org/0009-0003-6208-4502"]},"institutions":[{"id":"https://openalex.org/I4210117660","display_name":"Desert Regional Medical Center","ror":"https://ror.org/02jqk1764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210117660"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Timothy Tyler","raw_affiliation_strings":["Comprehensive Cancer Center, Desert Regional Medical Center, 1180 N. Indian Canyon Dr., E-218, Palm Springs, CA 92262","Timothy Tyler PharmD FCSHP, Director of Pharmacy Services, Comprehensive Cancer Center, Desert Regional Medical Center, 1180 N. Indian Canyon Dr., E-218, Palm Springs, CA 92262, fax 760/416-4726, TTyler@aptiumoncology.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, Desert Regional Medical Center, 1180 N. Indian Canyon Dr., E-218, Palm Springs, CA 92262","institution_ids":["https://openalex.org/I4210117660"]},{"raw_affiliation_string":"Timothy Tyler PharmD FCSHP, Director of Pharmacy Services, Comprehensive Cancer Center, Desert Regional Medical Center, 1180 N. Indian Canyon Dr., E-218, Palm Springs, CA 92262, fax 760/416-4726, TTyler@aptiumoncology.com","institution_ids":["https://openalex.org/I4210117660"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5113785207"],"corresponding_institution_ids":["https://openalex.org/I4210117660"],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":1.0917,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.79104956,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"43","issue":"5","first_page":"920","last_page":"927"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9679999947547913},{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.8489999771118164},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.9409999847412109},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.8889999985694885},{"id":"https://openalex.org/keywords/imatinib-intolerance","display_name":"imatinib intolerance","score":0.9750000238418579},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.6010000109672546},{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia","display_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","score":0.8529999852180481},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9520000219345093},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.9929999709129333},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6499999761581421}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.96185302734375},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9530113339424133},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7872900366783142},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5182899832725525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5104697942733765},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3514125943183899},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.22761231660842896}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1345/aph.1l570","doi":"https://doi.org/10.1345/aph.1l570","is_oa":false,"landing_page_url":"https://doi.org/10.1345/aph.1l570","pdf_url":null,"source":{"id":"https://openalex.org/S113426163","display_name":"Annals of Pharmacotherapy","issn_l":"0012-6578","issn":["0012-6578","1060-0280","1542-6270"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Pharmacotherapy","raw_type":"journal-article"},{"id":"pmid:19336654","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19336654","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Annals of pharmacotherapy","raw_type":"Comparative Study"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.955.4924","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.955.4924","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://aop.sagepub.com/content/43/5/920.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W1480179919","https://openalex.org/W1484834653","https://openalex.org/W1510546584","https://openalex.org/W1970962784","https://openalex.org/W1986058924","https://openalex.org/W1988586881","https://openalex.org/W1994309500","https://openalex.org/W1998990808","https://openalex.org/W2004492241","https://openalex.org/W2016116473","https://openalex.org/W2016656445","https://openalex.org/W2028728760","https://openalex.org/W2028959752","https://openalex.org/W2039201527","https://openalex.org/W2040396943","https://openalex.org/W2057718276","https://openalex.org/W2064831267","https://openalex.org/W2066099870","https://openalex.org/W2070683532","https://openalex.org/W2071645102","https://openalex.org/W2079446921","https://openalex.org/W2080125373","https://openalex.org/W2091137497","https://openalex.org/W2092606584","https://openalex.org/W2097946794","https://openalex.org/W2116153687","https://openalex.org/W2121391001","https://openalex.org/W2126742110","https://openalex.org/W2151968496","https://openalex.org/W2163773009","https://openalex.org/W2242087004","https://openalex.org/W2249113056","https://openalex.org/W2281742031","https://openalex.org/W2329648702","https://openalex.org/W2344241496","https://openalex.org/W2400188205","https://openalex.org/W2408824011","https://openalex.org/W2558733660","https://openalex.org/W2559555523","https://openalex.org/W2589955083","https://openalex.org/W2591514972"],"related_works":["https://openalex.org/W2160924881","https://openalex.org/W2145831684","https://openalex.org/W2116153687","https://openalex.org/W2340673163","https://openalex.org/W2084199623","https://openalex.org/W1523946531","https://openalex.org/W2248103587","https://openalex.org/W2029243071","https://openalex.org/W2046542169","https://openalex.org/W2979745721"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"discuss":[2],"the":[3,9,43,46,52,55,62,100,115,121,135,189,246,255],"new":[4],"dasatinib":[5,156,192,225],"dosing":[6],"regimen":[7,152,251],"for":[8,104,120,258],"treatment":[10,122],"of":[11,45,49,54,58,86,123,137,167,198,208],"chronic":[12,14,65,68],"phase":[13],"myelogenous":[15,66],"leukemia":[16,133],"(CP":[17],"CML)":[18],"in":[19,92,161,177,188],"patients":[20,108,125,162,209,223,259],"who":[21,210],"failed":[22],"or":[23,111,128,215],"were":[24],"intolerant":[25,113],"to":[26,114,149,212,241],"imatinib":[27],"therapy.":[28],"DATA":[29,80,96],"SOURCES:":[30],"Literature":[31],"published":[32,91],"between":[33,179],"July":[34],"2008":[35,38],"and":[36,51,75,84,202,252],"December":[37],"was":[39,118,147,173,186,219],"accessed":[40],"via":[41],"MEDLINE,":[42],"Proceedings":[44,53],"American":[47,56],"Society":[48,57],"Hematology,":[50],"Clinical":[59],"Oncology":[60],"using":[61],"key":[63],"words":[64],"leukemia,":[67,70],"myeloid":[69],"dasatinib,":[71],"imatinib,":[72],"nilotinib,":[73],"pharmacokinetics,":[74],"regimen.":[76],"STUDY":[77],"SELECTION":[78],"AND":[79],"EXTRACTION:":[81],"Meeting":[82],"abstracts":[83],"reports":[85],"major":[87],"Phase":[88,143],"1-3":[89],"studies":[90],"English":[93],"are":[94,112],"included.":[95],"SYNTHESIS:":[97],"Imatinib":[98],"is":[99,253],"standard":[101],"first-line":[102],"therapy":[103],"CML;":[105],"however,":[106],"some":[107],"develop":[109],"resistance":[110],"drug.":[116],"Dasatinib":[117,231],"approved":[119],"imatinib-resistant/intolerant":[124],"with":[126,153,163,194,245,260],"CML":[127],"Philadelphia":[129],"chromosome-positive":[130],"acute":[131],"lymphoblastic":[132],"at":[134],"dosage":[136,218],"70":[138,248],"mg":[139,158,227,233,249],"twice":[140],"daily.":[141,229],"A":[142],"3":[144],"dose-optimization":[145],"study":[146,169],"performed":[148],"compare":[150],"this":[151,168],"others,":[154],"including":[155],"100":[157,226,232],"once":[159,228,234],"daily,":[160],"CP":[164,261],"CML.":[165,262],"Results":[166],"showed":[170],"that":[171],"there":[172],"no":[174],"significant":[175],"difference":[176],"efficacy":[178],"these":[180],"2":[181],"regimens.":[182],"The":[183,206],"safety":[184],"profile":[185],"improved":[187],"100-mg":[190],"once-daily":[191],"arm":[193],"significantly":[195],"reduced":[196],"frequencies":[197],"grade":[199],"3-4":[200],"thrombocytopenia":[201],"all-grade":[203],"pleural":[204],"effusions.":[205],"number":[207],"had":[211],"discontinue,":[213],"reduce,":[214],"interrupt":[216],"their":[217],"also":[220],"less":[221],"among":[222],"taking":[224],"CONCLUSIONS:":[230],"daily":[235],"has":[236],"a":[237],"more":[238],"favorable":[239],"risk":[240],"benefit":[242],"assessment":[243],"compared":[244],"previous":[247],"twice-daily":[250],"now":[254],"recommended":[256],"schedule":[257]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}